Hims & Hers: Peptide Ruling A Positive, Operational Good Sense Makes 'Buy' Case (Upgrade)

Hims & Hers Health is upgraded from "Hold" to "Buy," driven by operational discipline and strategic opportunism despite sector volatility. HIMS leverages FDA panel momentum on peptides, expanding into personalized treatments while maintaining a robust telehealth platform and global reach. Management pursues a "best in market" approach to peptide launches, prioritizing clinical rigor, validated supply chains, and data transparency over speed. Despite $974 million in convertible notes and sector skepticism, HIMS targets $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, trading at ~2.5x forward sales.